Clinical impact of somatic genomic testing on breast cancer care
Clinical impact of somatic genomic testing on breast cancer care
Developments in our understanding of the molecular biology of breast cancer have had a direct impact on the investigations needed to provide optimal breast cancer care. Somatic genomic tests are now used routinely to inform decisions regarding adjuvant chemotherapy use in selected early breast cancer patients, and to identify patients with advanced disease who can potentially benefit from novel targeted agents. In this overview, we describe the somatic genomic tests currently available within the National Health Service (NHS) for early and advanced breast cancer patients. We review the underlying biology and the evidence base for clinical utility of these tests in routine clinical practice. In addition, we identify the somatic genomic biomarkers currently in use in breast cancer clinical trials that are most likely to influence future breast cancer management. We also consider the challenges associated with tissue-based genomic testing in advanced breast cancer and the role of circulating tumour deoxyribonucleic acid (ctDNA) testing.
Breast cancer, Genomic test, Somatic test
Khalid, T
a89abb5a-05ac-4a1e-8712-e65953e1516d
Cutress, R I
68ae4f86-e8cf-411f-a335-cdba51797406
Remer, M
4ce5d442-0a24-4265-aaad-ad13c1936715
Copson, E R
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Khalid, T
a89abb5a-05ac-4a1e-8712-e65953e1516d
Cutress, R I
68ae4f86-e8cf-411f-a335-cdba51797406
Remer, M
4ce5d442-0a24-4265-aaad-ad13c1936715
Copson, E R
a94cdbd6-f6e2-429d-a7c0-462c7da0e92b
Khalid, T, Cutress, R I, Remer, M and Copson, E R
(2024)
Clinical impact of somatic genomic testing on breast cancer care.
Clinical Oncology, 37, [103665].
(doi:10.1016/j.clon.2024.10.037).
Abstract
Developments in our understanding of the molecular biology of breast cancer have had a direct impact on the investigations needed to provide optimal breast cancer care. Somatic genomic tests are now used routinely to inform decisions regarding adjuvant chemotherapy use in selected early breast cancer patients, and to identify patients with advanced disease who can potentially benefit from novel targeted agents. In this overview, we describe the somatic genomic tests currently available within the National Health Service (NHS) for early and advanced breast cancer patients. We review the underlying biology and the evidence base for clinical utility of these tests in routine clinical practice. In addition, we identify the somatic genomic biomarkers currently in use in breast cancer clinical trials that are most likely to influence future breast cancer management. We also consider the challenges associated with tissue-based genomic testing in advanced breast cancer and the role of circulating tumour deoxyribonucleic acid (ctDNA) testing.
Text
PIIS0936655524004503
- Version of Record
More information
e-pub ahead of print date: 19 October 2024
Additional Information:
Publisher Copyright:
© 2024 The Authors
Keywords:
Breast cancer, Genomic test, Somatic test
Identifiers
Local EPrints ID: 496539
URI: http://eprints.soton.ac.uk/id/eprint/496539
ISSN: 0936-6555
PURE UUID: 3bfd5e96-38b6-465a-ab08-63dbd0bc72b8
Catalogue record
Date deposited: 17 Dec 2024 17:53
Last modified: 17 Dec 2024 17:56
Export record
Altmetrics
Contributors
Author:
T Khalid
Author:
M Remer
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics